The Latest Breaking News from Raymond James

CSX Corp's (NASDAQ:CSX) price target has been raised by two analysts post Q1 results. Raymond James analyst Patrick Tyler Brown raised CSX’s price target to $40 (an upside of 10%) from $39 while maintaining the Outperform rating on the shares. The analyst states that CSX continues to execute its PSR initiatives to drive operational improvement,…

Raymond James thinks Abbott Laboratories' (NYSE: ABT) 1Q results were solid and demonstrated the durable nature of ABT's portfolio, as three out of four business segments grew over 10% organically, with Nutrition growing 8% 

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 11 strange trades.

Abbott Laboratories (NYSE:ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50. Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02 billion. Worldwide sales, excluding…

Qualtrics International Inc's (NASDAQ:XM) April 15 proxy filing also disclosed new ACV and retention metrics pertinent to investors, Raymond James observed.  Qualtrics added $365.1 million in new software ACV billings in 2021, effectively aligning with the target performance level of $365.0 million.  Total research services billing of $160.1 million also were effectively in-line…

Raymond James observed Gartner's report that saw Coupa Software Inc (NASDAQ: COUP) gain ~135 points of software market share in procurement, with a growth of 35%, more than double the industry average at ~16%.

Upgrades

Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Intuitive Surgical Inc (NASDAQ:ISRG) will report Q1 FY22 earnings. Analysts believe that the Med Tech investors have become somewhat 'paralyzed' given the macro/factor-driven concerns.  On the macro, investor attention seems to be focused less on revenue growth and more…

Upgrades

Raymond James has decided to maintain its Strong Buy rating of Copa Holdings (NYSE:CPA) and lower its price target from $115.00 to $110.00. Shares of Copa Holdings are trading up 2.68% over the last 24 hours, at $78.04 per share.

Raymond James analyst Savanthi Syth lowered the price target on Copa Holdings (NYSE:CPA) to $110 (an upside of 42%) from $115 while maintaining the Strong Buy rating on the shares. Copa is a Panamanian holding company consisting of Copa Airlines and Copa Colombia. The analyst revised the forecast to reflect higher fuel price forecasts, particularly…